INmune Bio Inc (NASDAQ:INMB) price on Friday, June 13, fall -2.78% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $7.70.
A look at the stock’s price movement, the close in the last trading session was $7.92. Turning to its 52-week performance, $10.50 and $4.32 were the 52-week high and 52-week low respectively. Overall, INMB moved 3.63% over the past month.
INmune Bio Inc’s market cap currently stands at around $178.72 million, with investors looking forward to this quarter’s earnings report slated for in July.
INMB’s current price about 1.57% and 2.21% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 51.68, while 7-day volatility ratio is 3.06% and 3.22% in the 30-day chart. Further, INmune Bio Inc (INMB) has a beta value of 1.57, and an average true range (ATR) of 0.51. Analysts have given the company’s stock an average 52-week price target of $22, forecast between a low of $22 and high of $22. Looking at the price targets, the low is -185.71% off current price level while to achieve the yearly target high, price needs to move -185.71%. Nonetheless, investors will most likely welcome a -185.71% jump to $22 which is the analysts’ median price.
If we refocus on INmune Bio Inc (NASDAQ:INMB), historical trading data shows that trading volumes averaged 320.08K over the past 3 months. The company’s latest data on shares outstanding shows there are 22.93 million shares.
The 28.90% of INmune Bio Inc’s shares are in the hands of company insiders while institutional holders own 25.53% of the company’s shares. Current price change has pushed the stock 64.88% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the INMB stock continues to rise going into the next quarter.
